You're contacting media contact of this press release

Title: Traditional American Pharmaceutical Companies Aim for Global Hair Loss Treatment Market, Launching Comprehensive Hair Loss Products in China

Dusseldorf, Germany, 24th Jun 2024 - Traditional American pharmaceutical companies are targeting the global hair loss treatment market with their comprehensive hair loss ingredient, ProBico (PBCo), making its debut at 'HNC 2024' in Shanghai. The exhibition, held from June 19-21 at the Shanghai National Exhibition and Convention Center (NECC), features over 2,000 companies and is expected to attract more than 100,000 visitors.These American companies, which have led hair loss ingredient exports for a decade, plan to strengthen their presence in the Chinese market through ProBico-containing products. They have supplied raw materials for hair loss treatments to the Chinese market, including Taiwan, for the past 20 years. The companies aim to establish new export footholds for both B2B and B2C transactions at this expo.ProBico, composed of Proanthocyanidin, Biotin, and Coenzyme Q10, helps address major causes of hair loss, such as amino acid deficiency, inadequate hair synthesis, and follicle inflammation. Each ingredient is backed by patented technology and FDA GRAS (Generally Recognized As Safe) certification, ensuring high safety and efficacy.An executive from one of the American pharmaceutical companies stated, "China, the world's second-largest health food market after the US, has a penetration rate of only 20%, indicating significant growth potential. Having proven the excellence of ProBico in over 55 countries, we are committed to leading the 'globalization of hair loss treatment' by actively entering the Chinese market."US : ProbiCo中国 : 普洛维科日本 : プロビコ한국어 : 프로비코भारत : प्रोविकोFrançais : ProviCo

This press release is issued by King Newswire